Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients

15 Sept 2006

Abstract excerpt

PURPOSE: Germinal gene polymorphisms can explain a part of the interpatient pharmacodynamic variability of anticancer drugs, particularly fluoropyrimidines. Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD). EXPERIMENTAL DESIGN:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to Chemotherapy-induced cardiotoxicity and mitigation
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17000685
DOI: 10.1158/1078-0432.ccr-06-0320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of Capecitabine in Advanced Breast Cancer PatientsPMID 17000685Read ↗

Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).Semantic proximity Read ↗

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.Semantic proximity Read ↗

The role of pharmacogenetics in capecitabine efficacy and toxicity.Semantic proximity Read ↗

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.Semantic proximity Read ↗

Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.Semantic proximity Read ↗

New advances in DPYD genotype and risk of severe toxicity under capecitabine.Semantic proximity Read ↗

Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.Semantic proximity Read ↗

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast CancerSemantic proximity Read ↗

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.Semantic proximity Read ↗

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.Semantic proximity Read ↗

Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.Semantic proximity Read ↗

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.